First author | Study design | Sample size | RA patients | SpA patients | PsA patients | Outcome of COVID-19 patients with inflammatory arthropathies | Prognostic factors |
---|---|---|---|---|---|---|---|
FAI2R /SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors | Observational study | 694 | 213 | 165 | 70 | Severe COVID-19/hospitalization in RA: 29; SpA: 5; PsA: 6 Death in RA: 20; SpA: 1; PsA: 3 | Older age Comorbidities Longer term of GCs |
Gianfrancesco et al. | Observational study | 600 | 225 | 48 | 74 | Severe COVID-19/hospitalization in RA: 104; SpA: 16; PsA: 22 Death in the overall cohort including also CTD: 55 | Older age Comorbidities Higher doses of GCs |
Hasseli et al. | Retrospective observational study | 468 | 146 | 125 | * | Severe COVID-19/hospitalization in RA: 79; SpA: 20 severe COVID-19 Death in the overall cohort including also CTD: 19 | Older age Comorbidities Treatment with GCs at doses > 5 mg/day Moderate to high RMD disease activity |
Montero et al. | Retrospective observational study | 62 | 20 | 16 | * | Severe COVID-19/hospitalization in RA: 15; SpA: 11 Death in the overall cohort including also CTD: 10 | Male Gender Preexisting lung disease Treatment with GC at dose > 5 mg/day |
Pang et al. | Observational study | 21 | 15 | – | – | Severe COVID-19/hospitalization in RA: 15 0 death | Comorbidities |
Cheng et al. | Observational study | 5 | 4 | – | – | 5 hospitalised 0 death | Not reported |
Marques et al. | Observational study | 334 | 95 | 45 | 23 | 110 hospitalised 28 death | Age > 50 years Treatment with GCs and cyclophosphamide |